ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 586

High Prevalence of Anti-CD-74 Antibodies with Specificity for the Class II-Associated Invariant Chain Peptide in Patients with Axial Spondyloarthritis but Not in Controls

Xenofon Baraliakos1, Niklas T. Baerlecken2, Frank Heldmann3, Torsten Witte4 and Jürgen Braun3, 1Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, 2Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: The pathogenesis of axial spondyloarthritis (axSpA) is still unclear. Based on the strong association with HLA-B27 and ERAP-1, T cells are believed to play a major role but a role of B cells seems also possible. Autoantibodies have not been frequently found in axSpA but recently anti-CD74 antibodies with specificity to a class II-associated invariant chain peptide (CLIP) have been detected. We studied the prevalence of antibodies against CLIP (anti-CLIP-ABs) in patients with axSpA in comparison to controls and determine their sensitivity and specificity.

Methods: Sera of patients with axSpA and non-SpA were analyzed for IgG- antibodies against CD74 using an ELISA with specificity for CLIP, developed in cooperation with AESKU Diagnostics (Germany). A cut-off of ≥4 standard deviations of arbitrary units (AU) from the mean serum level was used to differentiate results. The laboratory workers were completely blinded for the clinical data.

Results: A total of 145 sera from 94 patients with axSpA and 51 with other diseases were analyzed. The patient demographics differed: axSpA patients were more often male and younger. The HLA-B27 status was available in 72 patients. Anti-CLIP-ABs were detected in 85.1% in axSpA but in only 7.8% in non-SpA patients (p£0.0001). Higher levels of anti-CLIP-ABs were found in axSpA vs. non-SpA: mean 14.5 vs. 0.8 AU (p£0.0001). The sensitivity of anti-CLIP-ABs for a diagnosis of axSpA was 85.1% and the specificity 92.2%, with a positive likelihood ratio (LR) of 10.8 and a negative LR of 0.08. The relative contribution of anti-CLIP-ABs and HLA-B27 was largely similar: 87.5% of the patients with axSpA were positive for both, but only 14.9% were anti-CLIP-negative while 23.6% were HLA-B27-negative.

Conclusion: Anti-CLIP antibodies were strongly associated with axSpA including AS. The LR for diagnosing AS was even higher than for HLA-B27. More studies using this promising new method in patients with non-radiographic axial SpA or peripheral SpA are needed to establish its usefulness in clinical practice.


Disclosure:

X. Baraliakos,
None;

N. T. Baerlecken,
None;

F. Heldmann,
None;

T. Witte,
None;

J. Braun,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-prevalence-of-anti-cd-74-antibodies-with-specificity-for-the-class-ii-associated-invariant-chain-peptide-in-patients-with-axial-spondyloarthritis-but-not-in-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology